Efficacy and Safety of Tusa with Pembrolizumab and Chemotherapy in NSCLC: CARMEN-LC05 Study
August 8th 2023Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.
Watch
Assessing Available CAR T-Cell Agents for DLBCL
August 7th 2023Frederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.
Watch
Behind the FDA Approval of Dostarlimab/Chemo for dMMR/MSI-H Endometrial Cancer
August 1st 2023Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
Watch